# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a rang...
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against i...
Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19....
Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a rang...